Whitehawk Therapeutics, Inc. SEC filings WHWK
Whitehawk Therapeutics, Inc. has 671 filings in SEC EDGAR's recent list, going back to Feb 1, 2008. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 10, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Apr 28, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 11, 2025 |
| DEFA14A | Additional proxy material | Feb 19, 2025 | — |
| DEFA14A | Additional proxy material | Feb 18, 2025 | — |
| DEFA14A | Additional proxy material | Feb 5, 2025 | — |
| DEFM14A | Filing | Jan 31, 2025 | — |
| PREM14A | Filing | Jan 21, 2025 | Jan 21, 2025 |
| DEFA14A | Additional proxy material | Dec 30, 2024 | — |
| DEFA14A | Additional proxy material | Dec 20, 2024 | — |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 11, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | — |
| DEFA14A | Additional proxy material | Apr 26, 2022 | — |
| DEF 14A | Proxy statement | Apr 26, 2022 | Jun 14, 2022 |
| DEFM14A | Filing | Jul 8, 2021 | — |
| PREM14A | Filing | Jun 21, 2021 | Jun 21, 2021 |
| DEFA14A | Additional proxy material | Jun 9, 2021 | — |
| DEF 14A | Proxy statement | Jun 9, 2021 | Jul 22, 2021 |
| DEFA14A | Additional proxy material | Jun 4, 2021 | — |
| DEFA14A | Additional proxy material | May 20, 2021 | — |
| DEFA14A | Additional proxy material | May 17, 2021 | — |
| DEFA14A | Additional proxy material | Jun 8, 2020 | — |
| DEFA14A | Additional proxy material | May 8, 2020 | — |
| DEFA14A | Additional proxy material | Apr 27, 2020 | — |
| DEF 14A | Proxy statement | Apr 27, 2020 | Jun 24, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2020 | Jun 24, 2020 |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 18, 2019 |
| DEF 14A | Proxy statement | May 15, 2018 | Jun 20, 2018 |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- WHWK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Morristown, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1422142
- Former names
- Aadi Bioscience, Inc. (until Mar 18, 2025); Aerpio Pharmaceuticals, Inc. (until Aug 23, 2021); ZETA ACQUISITION CORP II (until Mar 13, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.